Gennex Laboratories Limited (BOM:531739)

Market Cap	3.08B
Revenue (ttm)	1.49B
Net Income (ttm)	185.52M
Shares Out	227.45M
EPS (ttm)	0.78
PE Ratio	17.43
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	212,986
Average Volume	445,535
Open	13.77
Previous Close	13.49
Day's Range	13.31 - 13.77
52-Week Range	10.84 - 19.05
Beta	0.50
RSI	42.39
Earnings Date	Nov 14, 2025

About Gennex Laboratories

Gennex Laboratories Limited manufactures and sells bulk drugs, intermediates, and biotech products. The company offers Guaifenesin, an expectorant used as a mucolyte; Methocarbamol for skeletal muscle relaxant; Fexofenadine Hcl for treating antihistamines; Phenazopyridine Hcl for the treatment of urinary tract analgesic; Fluconazole for antifungals; Melitracen Hcl for treating tricyclic antidepressant; Sertraline Hcl, a selective serotonin reuptake inhibitor; Chlorphenesin and Mephenesin for muscle relaxant; and Allopurinol, a xanthine oxidase ...

• Industry: Pharmaceutical Preparations
• Founded: 1985
• Employees: 115
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 531739

Financial Performance

In 2024, Gennex Laboratories's revenue was 1.38 billion, an increase of 59.03% compared to the previous year's 867.14 million. Earnings were 181.23 million, an increase of 37.55%.